Frankfurt - Delayed Quote EUR

CEL-SCI Corporation (LSRM.F)

0.2232

+0.0004

+(0.18%)

As of 8:07:05 AM GMT+2. Market Open.

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

VIENNA, Va., April 23, 2025--CEL-SCI to file for Regulatory Approval of Multikine in Saudi Arabia—Pursuing local partnerships to serve Middle East and North Africa Market

Business Wire 20 days ago

CVM
New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

VIENNA, Va., April 08, 2025--New study in the scientific journal "Cancer Cell" supports CEL-SCI’s strategy to seek early approval for Multikine.

Business Wire last month

CVM
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

VIENNA, Va., March 24, 2025--CEL-SCI reports new data. Treatment with Multikine resulted in up to 95% improvement in Quality of Life for Head and Neck Cancer Patients.

Business Wire last month

CVM
CEL-SCI Announces Closing of $2.5 Million Offering

VIENNA, Va., March 18, 2025--CEL-SCI announces closing of $2.5 million offering .

Business Wire last month

CVM
CEL-SCI Announces Pricing of $2.5 Million Offering

VIENNA, Va., March 17, 2025--CEL-SCI announces pricing of $2.5 million offering.

Business Wire last month

CVM
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

VIENNA, Va., March 17, 2025--Head and Neck Cancer Registration Study Protocol clears FDA review—in talks with potential partners Interested in commercialization of Multikine.

Business Wire last month

CVM
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

VIENNA, Va., March 14, 2025--Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

Business Wire last month

CVM
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

VIENNA, Va., February 20, 2025--CEL-SCI to initiate Multikine Confirmatory Phase 3 Cancer Trial.

Business Wire 2 months ago

CVM
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

VIENNA, Va., February 18, 2025--CEL-SCI reports fiscal Q1 2025 financial results: Multikine shows pre-surgical tumor elimination and regression in just 3 weeks.

Business Wire 2 months ago

CVM
Cel-Sci: Fiscal Q1 Earnings Snapshot

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Friday reported a loss of $7.1 million in its fiscal first quarter.

Associated Press Finance 2 months ago

CVM
CVM: Fiscal Year 2024 Results

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reports fiscal year 2024 financial and operational results. The press release and Form 10-K filing encapsulate a year of preparation for confirmatory registration studies around the globe. CEL-SCI cleared its proposed 212-patient registration study of Multikine with the FDA. This narrowed the

Zacks Small Cap Research 3 months ago

CVM
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

VIENNA, Va., January 14, 2025--CEL-SCI reports fiscal 2024 results: set to commence confirmatory study that could bring new standard of care to head & neck cancer.

Business Wire 3 months ago

CVM
CEL-SCI Announces Closing of $5 Million Offering

VIENNA, Va., December 31, 2024--CEL-SCI announces closing of $5 million offering.

Business Wire 4 months ago

CVM
CEL-SCI Announces Pricing of $5 Million Public Offering

VIENNA, Va., December 30, 2024--CEL-SCI announces pricing of $5 million public offering.

Business Wire 4 months ago

CVM
CEL-SCI Announces Proposed Public Offering of Common Stock

VIENNA, Va., December 27, 2024--CEL-SCI announces proposed public offering of common stock.

Business Wire 4 months ago

CVM
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

VIENNA, Va., December 12, 2024--CEL-SCI highlights biological rationale for the use of Multikine in the Confirmatory Registration Head and Neck Cancer Study.

Business Wire 4 months ago

CVM
CVM: CRO Selected for Registrational Trial

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) has made progress advancing the prerequisites for the upcoming registrational trial, selecting the contract research organization (CRO) that will run it and coming to an agreement with the FDA on which biomarkers are appropriate for selecting patients. The view of oncologists as expressed by the

Zacks Small Cap Research 5 months ago

CVM
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

VIENNA, Va., November 07, 2024--U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025.

Business Wire 6 months ago

CVM
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

VIENNA, Va., October 22, 2024--FDA’s ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.

Business Wire 6 months ago

CVM
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

VIENNA, Va., October 01, 2024--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.

Business Wire 7 months ago

CVM

Performance Overview

Return	LSRM.F	S&P 500 (^GSPC)
YTD	-40.89%	+0.08%
1-Year	-82.79%	+12.20%
3-Year	-91.68%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CEL-SCI Corporation (LSRM.F)

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Cel-Sci: Fiscal Q1 Earnings Snapshot

CVM: Fiscal Year 2024 Results

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

CVM: CRO Selected for Registrational Trial

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Performance Overview